

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Clinical Practice Guideline Update

1. F. B. De Abreu, W. A. Wells, G. J. Tsongalis. . The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. *Am J Pathol* , 183(): 1075-83. . PMID 23920325
2. E. Crocetti, A. Caldarella, S. Ferretti, E. Ardanaz, P. Arveux, S. Bara, E. Barrios, M. J. Bento, A. Bordoni, C. Buzzoni, G. Candela, F. Colombani, P. Delafosse, M. Federico, J. Francart, A. Giacomini, P. Grosclaude, A. V. Guizard, I. Izarzugaza, I. Konzelmann, F. La Rosa, B. Lapotre, N. Leone, K. Ligier, L. Mangone, R. Marcos-Gragera, R. Martinez, M. J. Michelena, M. Michiara, A. Miranda, F. Molinie, C. Mugarza-Gomez, E. Paci, S. Piffer, M. Puig-Vives, C. Sacchetti, M. J. Sanchez, A. Traina, B. Tretarre, R. Tumino, E. Van Vaerenbergh, M. Velten, A. S. Woronoff. . Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries. *Breast* , 22(): 476-81. . PMID 23669022
3. F. Penault-Llorca, R. A. Coudry, W. M. Hanna, R. Y. Osamura, J. Ruschoff, G. Viale. . Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. *Breast* , 22(): 200-2. . PMID 23352656
4. M. Pekmezci, A. Szpadarska, C. Osipo, C. Ersahin. . The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma. *Patholog Res Int* , 2012(): 947041. . PMID 22482085
5. G. Cserni, M. Francz, E. Kalman, G. Kelemen, D. C. Komjathy, I. Kovacs, J. Kulka, L. Sarkadi, N. Udvarhelyi, L. Vass, A. Voros. . Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?. *Pathol Oncol Res* , 17(): 663-8. . PMID 21267685
6. M. Mathews, J. Newbury, E. M. Housser. . Shaping policy: the Canadian Cancer Society and the Hormone Receptor Testing Inquiry. *Curr Oncol* , 18(): 174-9. . PMID 21874116
7. M. E. Hammond, D. F. Hayes, A. C. Wolff. . Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. *J Clin Oncol* , 29(): e458. . PMID 21502545
8. M. Mostafa, M. Larsen, R. Love. . Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women. *J Bangladesh Coll Phys Surg* , 28(): 157-162. . PMID 22279410
9. C. A. Krusche, R. von Wasielewski, J. Ruschoff, A. Fisseler-Eckhoff, H. H. Kreipe. . [Interlaboratory trials for quality assurance of breast cancer biomarkers in Germany]. *Pathologe* , 29(): 315-20. . PMID 18504581
10. A. Sapino, C. Marchio, R. Senetta, I. Castellano, L. Macri, P. Cassoni, G. Ghisolfi, M. Cerrato, E. D'Ambrosio, G. Bussolati. . Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. *Virchows Arch* , 449(): 288-96. . PMID 16770642
11. C. C. Cheung, D. Banerjee, P. J. Barnes, R. C. Berendt, J. Butany, S. Canil, B. A. Clarke, H. El-Zimaity, J. Garratt, L. Geldenhuys, C. B. Gilks, L. Manning, M. Mengel, B. Perez-Ordóñez, D. Pilavdzic, R. Riddell, P. E. Swanson, E. E. Torlakovic. . Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry. *Am J Clin Pathol* , 142(): 629-33. . PMID 25319977

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

12. C. C. Cheung, H. Neufeld, L. A. Lining, D. Pilavdzic, M. Copete, J. Garratt, B. Gilks, E. E. Torlakovic. . The laboratory score/reference method score ratio (LSRSR) is a novel tool for monitoring laboratory performance in immunohistochemistry proficiency testing of hormone receptors in breast cancer: the CIQC experience. *Am J Clin Pathol* , 136(): 67-73. . PMID 21685033
13. F. Acevedo, M. Camus, C. Vial, S. Panay, M. Abarca, F. Dominguez, C. Sanchez. . [Predictive value of conventional immuno-histochemical biomarkers in breast cancer]. *Rev Med Chil* , 143(): 724-32. . PMID 26230555
14. E. K. Adjei, O. Owusu-Afriyie, B. Awuah, H. Stalsberg. . Hormone receptors and Her2 expression in breast cancer in sub-Saharan Africa. A comparative study of biopsies from Ghana and Norway. *Breast J* , 20(): 308-11. . PMID 24708149
15. D. G. Albertson. . Conflicting evidence on the frequency of ESR1 amplification in breast cancer. *Nat Genet* , 40(): 821-2. . PMID 18583976
16. 566: H. R. Ali, M. Irwin, L. Morris, S. J. Dawson, F. M. Blows, E. Provenzano, B. Mahler-Araujo, P. D. Pharoah, N. A. Walton, J. D. Brenton, C. Caldas. . Astronomical algorithms for automated analysis of tissue protein expression in breast cancer. *Br J Cancer* , 108(): 602-12. . PMID 23329232
17. T. Amaral, S. J. McKenna, K. Robertson, A. Thompson. . Classification and immunohistochemical scoring of breast tissue microarray spots. *IEEE Trans Biomed Eng* , 60(): 2806-14. . PMID 23715601
18. V. Becette, F. Lerebours, F. Spyrtos, E. Menet, M. Tubiana-Hulin, M. Briffod. . Immunomarker studies of fine-needle cytopuncture cell blocks for tumor response prediction after preoperative chemotherapy and prognosis in operable nonmetastatic primary breast carcinoma. *Breast J* , 17(): 121-8. . PMID 21306468
19. Y. Chen, C. Chen, B. Yang, Q. Xu, F. Wu, F. Liu, X. Ye, X. Meng, B. Mougin, G. Liu, Z. Shen, Z. Shao, J. Wu. . Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. *Cancer Lett* , 302(): 63-8. . PMID 21220187
20. R. D. Daltoe, K. P. Madeira, A. A. de Carvalho, L. C. de Rezende, I. V. Silva, L. B. Rangel. . Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system. *Int J Clin Exp Pathol* , 7(): 331-9. . PMID 24427354
21. X. Du, X. Q. Li, L. Li, Y. Y. Xu, Y. M. Feng. . The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. *Breast Cancer Res Treat* , 138(): 59-67. . PMID 23397283
22. A. Dvorkin-Gheva, J. A. Hassell. . Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples. *PLoS One* , 6(): e26023. . PMID 22022496
23. B. Ejlersen, J. Aldridge, K. V. Nielsen, M. M. Regan, K. L. Henriksen, A. E. Lykkesfeldt, S. Muller, R. D. Gelber, K. N. Price, B. B. Rasmussen, G. Viale, H. Mouridsen. . Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. *Ann Oncol* , 23(): 1138-44. . PMID 21986093

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

24. L. P. Feeley, A. M. Mulligan, D. Pinnaduwege, S. B. Bull, I. L. Andrulis. . Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. *Mod Pathol* , 27(): 554-61. . PMID 24051696
25. A. Glajcar, K. Kaczmarczyk, J. Szpor, K. Okon. . Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma. *Folia Histochem Cytobiol* , 51(): 326-32. . PMID 24497138
26. T. Iwamoto, G. Bianchini, D. Booser, Y. Qi, C. Coutant, C. Y. Shiang, L. Santarpi, J. Matsuoka, G. N. Hortobagyi, W. F. Symmans, F. A. Holmes, J. O'Shaughnessy, B. Hellerstedt, J. Pippen, F. Andre, R. Simon, L. Pusztai. . Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. *J Natl Cancer Inst* , 103(): 264-72. . PMID 21191116
27. M. R. Khoshnoud, B. Lofdahl, H. Fohlin, T. Fornander, O. Stal, L. Skoog, J. Bergh, B. Nordenskjold. . Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. *Breast Cancer Res Treat* , 126(): 421-30. . PMID 20957430
28. S. Kostopoulos, D. Glotsos, D. Cavouras, A. Daskalakis, I. Kalatzis, P. Georgiadis, P. Bougioukos, P. Ravazoula, G. Nikiforidis. . Computer-based association of the texture of expressed estrogen receptor nuclei with histologic grade using immunohistochemically-stained breast carcinomas. *Anal Quant Cytol Histol* , 31(): 187-96. . PMID 19736866
29. J. A. Kraus, D. J. Dabbs, S. Beriwal, R. Bhargava. . Semi-quantitative immunohistochemical assay versus oncotype DX((R)) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. *Mod Pathol* , 25(): 869-76. . PMID 22301704
30. H. H. Kreipe. . [Receptor detection in breast cancer. A decade of quality assurance trials in German-speaking pathology]. *Pathologe* , 32(): 357-9. . PMID 21847514
31. M. Nadji. . Quantitative immunohistochemistry of estrogen receptor in breast cancer: "much ado about nothing!". *Appl Immunohistochem Mol Morphol* , 16(): 105-7. . PMID 18227735
32. N. Patani, L. A. Martin, M. Dowsett. . Biomarkers for the clinical management of breast cancer: international perspective. *Int J Cancer* , 133(): 1-13. . PMID 23280579
33. P. Patil, P. O. Bachant-Winner, B. Haibe-Kains, J. T. Leek. . Test set bias affects reproducibility of gene signatures. *Bioinformatics* , 31(): 2318-23. . PMID 25788628
34. I. Pinhel, M. Hills, S. Drury, J. Salter, G. Sumo, R. A'Hern, J. M. Bliss, I. Sestak, J. Cuzick, P. Barrett-Lee, A. Harris, M. Dowsett. . ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. *Breast Cancer Res* , 14(): R46. . PMID 22417870
35. X. Zhao, E. A. Rodland, T. Sorlie, H. K. Vollen, H. G. Russnes, V. N. Kristensen, O. C. Lingjaerde, A. L. Borresen-Dale. . Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. *BMC Cancer* , 14(): 211. . PMID 24645668
36. L. N. Chaudhary, Z. Jawa, A. Szabo, A. Visotcky, C. R. Chitambar. . Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. *Hematol Oncol Stem Cell Ther* , (): . . PMID 26808222

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

37. E. G. East, J. C. Pang, K. M. Kidwell, J. M. Jorns. . Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma. *Am J Clin Pathol* , 144(): 952-9. . PMID 26573003
38. T. Shen, M. Brandwein-Gensler, O. Hameed, G. P. Siegal, S. Wei. . Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. *Hum Pathol* , 46(): 1776-84. . PMID 26363528
39. T. Hasan, B. Carter, N. Denic, L. Gai, J. Power, K. Voisey, K. R. Kao. . Evaluation of cell-line-derived xenograft tumours as controls for immunohistochemical testing for ER and PR. *J Clin Pathol* , 68(): 746-51. . PMID 26092992
40. S. R. Sompuram, K. Vani, B. Tracey, D. A. Kamstock, S. A. Bogen. . Standardizing Immunohistochemistry: A New Reference Control for Detecting Staining Problems. *J Histochem Cytochem* , 63(): 681-90. . PMID 25940339
41. B. C. Calhoun, L. C. Collins. . Predictive markers in breast cancer: An update on ER and HER2 testing and reporting. *Semin Diagn Pathol* , 32(): 362-9. . PMID 25770732
42. C. J. VandenBussche, A. Cimino-Mathews, B. H. Park, L. A. Emens, T. N. Tsangaris, P. Argani. . Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. *Am J Surg Pathol* , 39(): 939-47. . PMID 25871620
43. T. J. Dekker, S. ter Borg, G. K. Hooijer, S. L. Meijer, J. Wesseling, J. E. Boers, E. Schuurin, J. Bart, J. van Gorp, P. Bult, S. A. Riemersma, C. H. van Deurzen, H. F. Sleddens, W. E. Mesker, J. R. Kroep, V. T. Smit, M. J. van de Vijver. . Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. *Breast Cancer Res Treat* , 152(): 253. . PMID 26105796
44. T. J. Dekker, S. ter Borg, G. K. Hooijer, S. L. Meijer, J. Wesseling, J. E. Boers, E. Schuurin, J. Bart, J. van Gorp, P. Bult, S. A. Riemersma, C. H. van Deurzen, H. F. Sleddens, W. E. Mesker, J. R. Kroep, V. T. Smit, M. J. van de Vijver. . Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. *Breast Cancer Res Treat* , 152(): 247-52. . PMID 26041687
45. J. Niu, G. Andres, K. Kramer, M. N. Kundranda, R. H. Alvarez, E. Klimant, A. R. Parikh, B. Tan, E. D. Staren, M. Markman. . Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. *Onco Targets Ther* , 8(): 3323-8. . PMID 26648736
46. J. Salmen, J. Neugebauer, P. A. Fasching, L. Haeberle, J. Huober, A. Wockel, C. Rauh, F. Schuetz, T. Weissenbacher, B. Kost, E. Stickeler, M. Klar, M. Orlowska-Volk, M. Windfuhr-Blum, J. Heil, J. Rom, C. Sohn, T. Fehm, S. Mohrmann, C. R. Loehberg, A. Hein, R. Schulz-Wendtland, A. D. Hartkopf, S. Y. Brucker, D. Wallwiener, K. Friese, A. Hartmann, M. W. Beckmann, W. Janni, B. Rack. . Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. *Breast Cancer Res Treat* , 148(): 143-51. . PMID 25253172
47. C. H. Yip, A. Rhodes. . Estrogen and progesterone receptors in breast cancer. *Future Oncol* , 10(): 2293-301. . PMID 25471040

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

48. Z. Zhang, J. Wang, K. A. Skinner, M. Shayne, S. I. Hajdu, H. Bu, D. G. Hicks, P. Tang. . Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. *Histopathology* , 65(): 508-16. . PMID 24620991
49. P. L. Fitzgibbons, D. A. Dillon, R. Alsabeh, M. A. Berman, D. F. Hayes, D. G. Hicks, K. S. Hughes, S. Nofech-Mozes. . Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. *Arch Pathol Lab Med* , 138(): 595-601. . PMID 24236805
50. G. Viale, L. Slaets, J. Bogaerts, E. Rutgers, L. van't Veer, M. J. Piccart-Gebhart, F. A. de Snoo, L. Stork-Sloots, L. Russo, P. Dell'Orto, J. van den Akker, A. Glas, F. Cardoso. . High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. *Ann Oncol* , 25(): 816-23. . PMID 24667714
51. S. Liessem, W. Winkens, D. Jonigk, R. V. Wasielewski, A. Fisseler-Eckhoff, J. Ruschoff, H. H. Kreipe. . [Determination of tumor biological parameters in breast cancer: round robin testing for quality assurance]. *Pathologe* , 35(): 61-71. . PMID 24496992
52. A. O. Oluwasola, D. Malaka, A. I. Khramtsov, O. F. Ikpat, A. Odetunde, O. O. Adeyanju, W. E. Sveen, A. G. Falusi, D. Huo, O. I. Olopade. . Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. *Ann Diagn Pathol* , 17(): 526-30. . PMID 24095629
53. S. Maleki, O. Dorokhova, J. Sunkara, K. Schlesinger, M. Suhrland, M. H. Oktay. . Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells. *Diagn Cytopathol* , 41(): 864-70. . PMID 23447357
54. M. M. Hefti, R. Hu, N. W. Knoblauch, L. C. Collins, B. Haibe-Kains, R. M. Tamimi, A. H. Beck. . Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. *Breast Cancer Res* , 15(): R68. . PMID 23971947
55. K. Chubbs. . The estrogen receptor/progesterone receptor testing errors in Newfoundland and Labrador: a journey of hope, health, and healing. *Healthc Manage Forum* , 26(): 196-9. . PMID 24696944
56. S. Nofech-Mozes, E. T. Vella, S. Dhesy-Thind, W. M. Hanna. . Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer. *Clin Oncol (R Coll Radiol)* , 24(): 684-96. . PMID 22608362
57. S. Li, X. Yang, Y. Zhang, L. Fan, F. Zhang, L. Chen, Y. Zhou, X. Chen, J. Jiang. . Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis. *Breast Cancer Res Treat* , 135(): 325-34. . PMID 22527109
58. Z. Maleki, S. Shariat, M. Mokri, M. Atri. . ER-negative /PR-positive breast carcinomas or technical artifacts in immunohistochemistry?. *Arch Iran Med* , 15(): 366-9. . PMID 22642247
59. I. Z. Yildiz-Aktas, D. J. Dabbs, K. L. Cooper, M. Chivukula, K. McManus, R. Bhargava. . The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. *Am J Clin Pathol* , 137(): 691-8. . PMID 22523206
60. S. Nofech-Mozes, E. T. Vella, S. Dhesy-Thind, K. L. Hagerty, P. B. Mangu, S. Temin, W. M. Hanna. . Systematic review on hormone receptor testing in breast cancer. *Appl Immunohistochem Mol Morphol* , 20(): 214-63. . PMID 22505008

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

61. N. Makretsov, C. B. Gilks, R. Alaghebandan, J. Garratt, L. Quenneville, J. Mercer, D. Palavdzic, E. E. Torlakovic. . Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values. *Arch Pathol Lab Med* , 135(): 874-81. . PMID 21732777
62. A. Shabaik, G. Lin, M. Peterson, F. Hasteh, A. Tipps, B. Datnow, N. Weidner. . Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. *Diagn Cytopathol* , 39(): 328-32. . PMID 21488175
63. T. Hung, R. Wolber, J. Garratt, S. Kalloger, C. B. Gilks. . Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. *Pathology* , 42(): 637-42. . PMID 21080872
64. A. Rhodes, J. Sarson, E. E. Assam, S. J. Dean, E. C. Cribb, A. Parker. . The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. *Am J Clin Pathol* , 134(): 621-32. . PMID 20855644
65. M. E. Hammond, D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, P. L. Fitzgibbons, G. Francis, N. S. Goldstein, M. Hayes, D. G. Hicks, S. Lester, R. Love, P. B. Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J. N. Schwartz, F. C. Sweep, S. Taube, E. E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. B. Williams, J. L. Wittliff, A. C. Wolff. . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch Pathol Lab Med* , 134(): e48-72. . PMID 20586616
66. M. E. Hammond, D. F. Hayes, A. C. Wolff, P. B. Mangu, S. Temin. . American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Oncol Pract* , 6(): 195-7. . PMID 21037871
67. S. J. Aitken, J. S. Thomas, S. P. Langdon, D. J. Harrison, D. Faratian. . Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. *Ann Oncol* , 21(): 1254-61. . PMID 19858088
68. P. L. Fitzgibbons, D. A. Murphy, M. E. Hammond, D. C. Allred, P. N. Valenstein. . Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. *Arch Pathol Lab Med* , 134(): 930-5. . PMID 20524870
69. M. E. Hammond, D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, P. L. Fitzgibbons, G. Francis, N. S. Goldstein, M. Hayes, D. G. Hicks, S. Lester, R. Love, P. B. Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J. N. Schwartz, F. C. Sweep, S. Taube, E. E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. B. Williams, J. L. Wittliff, A. C. Wolff. . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *Arch Pathol Lab Med* , 134(): 907-22. . PMID 20524868

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

70. M. E. Hammond, D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, P. L. Fitzgibbons, G. Francis, N. S. Goldstein, M. Hayes, D. G. Hicks, S. Lester, R. Love, P. B. Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J. N. Schwartz, F. C. Sweep, S. Taube, E. E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. B. Williams, J. L. Wittliff, A. C. Wolff. . American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol* , 28(): 2784-95. . PMID 20404251
71. W. T. Barry, D. N. Kernagis, H. K. Dressman, R. J. Griffis, J. D. Hunter, J. A. Olson, J. R. Marks, G. S. Ginsburg, P. K. Marcom, J. R. Nevins, J. Geradts, M. B. Datto. . Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. *J Clin Oncol* , 28(): 2198-206. . PMID 20368555
72. G. B. Uy, A. V. Laudico, J. M. Carnate, F. G. Lim, A. M. Fernandez, R. R. Rivera, C. A. Mapua, R. R. Love. . Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients. *Clin Breast Cancer* , 10(): 154-9. . PMID 20299318
73. S. Siddiqui, D. L. Rimm. . Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. *Breast Cancer Res* , 12(): 113. . PMID 21176180
74. Pathologists' Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *Breast Care (Basel)* , 5(): 185-187. . PMID 21049068
75. D. C. Allred, R. W. Carlson, D. A. Berry, H. J. Burstein, S. B. Edge, L. J. Goldstein, A. Gown, M. E. Hammond, J. D. Iglehart, S. Moench, L. J. Pierce, P. Ravdin, S. J. Schnitt, A. C. Wolff. . NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. *J Natl Compr Canc Netw* , 7 Suppl 6(): S1-S21; quiz S22-3. . PMID 19755043
76. Rv Wasielewski, S. Hasselmann, J. Ruschoff, A. Fisseler-Eckhoff, H. Kreipe. . Proficiency testing of immunohistochemical biomarker assays in breast cancer. *Virchows Arch* , 453(): 537-43. . PMID 18958494
77. R. Rocha, C. Nunes, G. Rocha, F. Oliveira, F. Sanches, H. Gobbi. . Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. *Pathol Res Pract* , 204(): 655-62. . PMID 18565685
78. G. D. Francis, M. Dimech, L. Giles, A. Hopkins. . Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. *J Clin Pathol* , 60(): 1277-83. . PMID 17259294
79. L. B. Hardy, P. L. Fitzgibbons, J. D. Goldsmith, R. N. Eisen, M. B. Beasley, R. J. Souers, R. E. Nakhleh. . Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. *Arch Pathol Lab Med* , 137(): 19-25. . PMID 23276171
80. E. E. Torlakovic, G. Francis, J. Garratt, B. Gilks, E. Hyjek, M. Ibrahim, R. Miller, S. Nielsen, E. B. Petcu, P. E. Swanson, C. R. Taylor, M. Vyberg. . Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. *Appl Immunohistochem Mol Morphol* , 22(): 241-52. . PMID 24714041

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed public domain on April 29, 2019.

These draft materials should not be stored, adapted, cited, or redistributed in any manner.

81. S. Alkner, A. Ehinger, P. O. Bendahl, L. Ryden, M. Ferno. . Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy. *Eur J Cancer* , 51(): 2304-13. . PMID 26243193
82. K. H. Allison. . Estrogen receptor expression in breast cancer: we cannot ignore the shades of gray. *Am J Clin Pathol* , 130(): 853-4. . PMID 19019759
83. V. K. Anagnostou, A. W. Welsh, J. M. Giltane, S. Siddiqui, C. Liceaga, M. Gustavson, K. N. Syrigos, J. L. Reiter, D. L. Rimm. . Analytic variability in immunohistochemistry biomarker studies. *Cancer Epidemiol Biomarkers Prev* , 19(): 982-91. . PMID 20332259
84. S. Apple, R. Pucci, A. C. Lowe, I. Shintaku, S. Shapourifar-Tehrani, N. Moatamed. . The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. *Am J Clin Pathol* , 135(): 592-8. . PMID 21411782
85. M. Arnedos, A. Nerurkar, P. Osin, R. A'Hern, I. E. Smith, M. Dowsett. . Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). *Ann Oncol* , 20(): 1948-52. . PMID 19570962
86. L. Arnould, B. Coudert, P. Fumoleau. . Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?. *J Clin Oncol* , 27(): 2733; author reply 2734-5. . PMID 19380432
87. Nisa Azizun, Y. Bhurgri, F. Raza, N. Kayani. . Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. *Asian Pac J Cancer Prev* , 9(): 553-6. . PMID 19256737
88. Y. K. Bae, G. Gong, J. Kang, A. Lee, E. Y. Cho, J. S. Lee, K. S. Suh, D. W. Lee. . Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays. *Am J Surg Pathol* , 36(): 1817-25. . PMID 23154769
89. O. Bal, U. Yalcintas Arslan, A. Durnali, U. Uyetrk, A. Demirci, D. Tastekin, A. Ekinci, O. Esbah, I. Turker, O. Uysal Sonmez, B. Oksuzoglu. . Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients. *J BUON* , 20(): 28-34. . PMID 25778292
90. R. R. Bastien, A. Rodriguez-Lescure, M. T. Ebbert, A. Prat, B. Munarriz, L. Rowe, P. Miller, M. Ruiz-Borrego, D. Anderson, B. Lyons, I. Alvarez, T. Dowell, D. Wall, M. A. Segui, L. Barley, K. M. Boucher, E. Alba, L. Pappas, C. A. Davis, I. Aranda, C. Fauron, I. J. Stijleman, J. Palacios, A. Anton, E. Carrasco, R. Caballero, M. J. Ellis, T. O. Nielsen, C. M. Perou, M. Astill, P. S. Bernard, M. Martin. . PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. *BMC Med Genomics* , 5(): 44. . PMID 23035882
91. G. Bogina, G. Lunardi, F. Coati, G. Zamboni, S. Gori, L. Bortesi, M. Marconi, P. A. Cassandrini, M. Turazza, L. Cortesi, E. DeMatteis, G. Ficarra, T. Ibrahim, P. Serra, L. Medri, S. Giraudi, M. Lambertini, F. Carli, J. Foglietta, A. Sidoni, M. Nunzi, C. Ficorella, M. R. Diadema, L. Del Mastro. . Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. *Tumori* , 101(): 398-403. . PMID 26045108

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

92. J. M. Bordeaux, H. Cheng, A. W. Welsh, B. G. Haffty, D. R. Lannin, X. Wu, N. Su, X. J. Ma, Y. Luo, D. L. Rimm. . Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. *PLoS One* , 7(): e36559. . PMID 22606272
93. L. Braun, F. Mietzsch, P. Seibold, A. Schneeweiss, P. Schirmacher, J. Chang-Claude, H. Peter Sinn, S. Aulmann. . Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss. *Mod Pathol* , 26(): 1161-71. . PMID 23558572
94. T. Byers, S. Trujillo, L. Hines. . Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. *J Natl Cancer Inst* , 100(): 596. . PMID 18398102
95. R. D. Cardiff, N. E. Hubbard, J. A. Engelberg, R. J. Munn, C. H. Miller, J. E. Walls, J. Q. Chen, H. A. Velasquez-Garcia, J. J. Galvez, K. J. Bell, L. A. Beckett, Y. J. Li, A. D. Borowsky. . Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers. *Lab Invest* , 93(): 480-97. . PMID 23399853
96. S. Chen, C. M. Chen, K. D. Yu, R. J. Zhou, Z. M. Shao. . Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. *Ann Surg Oncol* , 19(): 3002-11. . PMID 22437200
97. X. Chen, Y. Yuan, Z. Gu, K. Shen. . Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. *Breast Cancer Res Treat* , 134(): 957-67. . PMID 22370627
98. Z. W. Chen, H. Neufeld, M. A. Copete, J. Garratt, C. B. Gilks, E. E. Torlakovic. . Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing. *Am J Clin Pathol* , 140(): 55-60. . PMID 23765534
99. C. C. Cheung, H. Neufeld, L. A. Lining, D. Pilavdzic, M. Copete, J. Garratt, B. Gilks, E. E. Torlakovic. . The laboratory score/reference method score ratio (LSRSR) is a novel tool for monitoring laboratory performance in immunohistochemistry proficiency testing of hormone receptors in breast cancer: the CIQC experience. *Am J Clin Pathol* , 136(): 67-73. . PMID 21685033
100. D. A. Cohen, D. J. Dabbs, K. L. Cooper, M. Amin, T. E. Jones, M. W. Jones, M. Chivukula, G. A. Trucco, R. Bhargava. . Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. *Am J Clin Pathol* , 138(): 796-802. . PMID 23161712
101. D. P. Cronin-Fenton, Y. Hellberg, K. L. Lauridsen, T. P. Ahern, J. P. Garne, C. Rosenberg, R. A. Silliman, H. T. Sorensen, T. L. Lash, S. Hamilton-Dutoit. . Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. *Acta Oncol* , 51(): 254-61. . PMID 22129357
102. A. DeCensi, G. Pruner, A. Guerrieri-Gonzaga. . Estrogen receptor in breast ductal carcinoma in situ: good cop, bad cop?. *J Clin Oncol* , 30(): 1384-6. . PMID 22393083
103. B. Deyarmin, J. L. Kane, A. L. Valente, R. van Laar, C. Gallagher, C. D. Shriver, R. E. Ellsworth. . Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. *Ann Surg Oncol* , 20(): 87-93. . PMID 22875649

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

104. A. M. Domanski, N. Monsef, H. A. Domanski, D. Grabau, M. Ferno. . Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. *Cytopathology* , 24(): 21-5. . PMID 22783929
105. M. Ekholm, D. Grabau, P. O. Bendahl, J. Bergh, G. Elmberger, H. Olsson, L. Russo, G. Viale, M. Ferno. . Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. *Acta Oncol* , 54(): 1040-8. . PMID 25959664
106. M. J. Ellis, Y. Tao, J. Luo, R. A'Hern, D. B. Evans, A. S. Bhatnagar, H. A. Chaudri Ross, A. von Kameke, W. R. Miller, I. Smith, W. Eiermann, M. Dowsett. . Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. *J Natl Cancer Inst* , 100(): 1380-8. . PMID 18812550
107. J. Ferguson, P. Chamberlain, H. M. Cramer, H. H. Wu. . ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies. *Diagn Cytopathol* , 41(): 575-81. . PMID 22807465
108. E. Garrett-Mayer, G. Parmigiani, X. Zhong, L. Cope, E. Gabrielson. . Cross-study validation and combined analysis of gene expression microarray data. *Biostatistics* , 9(): 333-54. . PMID 17873151
109. A. Gertych, S. Mohan, S. Maclary, S. Mohanty, K. Wawrowsky, J. Mirocha, B. Balzer, B. S. Knudsen. . Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis. *Diagn Pathol* , 9(): 213. . PMID 25421113
110. A. M. Gown. . Current issues in ER and HER2 testing by IHC in breast cancer. *Mod Pathol* , 21 Suppl 2(): S8-S15. . PMID 18437174
111. F. H. Groenendijk, W. Zwart, A. Floore, S. Akbari, R. Bernards. . Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics. *Breast Cancer Res Treat* , 140(): 475-84. . PMID 23912957
112. H. E. Gulbahce, R. Gamez, L. Dvorak, C. Forster, L. Varghese. . Concordance between tissue microarray and whole-section estrogen receptor expression and intratumoral heterogeneity. *Appl Immunohistochem Mol Morphol* , 20(): 340-3. . PMID 22495371
113. L. B. Hardy, P. L. Fitzgibbons, J. D. Goldsmith, R. N. Eisen, M. B. Beasley, R. J. Souers, R. E. Nakhleh. . Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. *Arch Pathol Lab Med* , 137(): 19-25. . PMID 23276171
114. T. Khoury, Y. Zakharia, W. Tan, S. Kulkarni, W. Liu, S. Zhang, G. E. Wilding, S. Edge. . Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy. *Breast J* , 17(): 180-6. . PMID 21306471
115. M. D. Kinsella, G. G. Birdsong, M. T. Siddiqui, C. Cohen, K. Z. Hanley. . Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples. *Diagn Cytopathol* , 41(): 192-8. . PMID 22611048

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

116. S. K. Kumar, N. Gupta, A. Rajwanshi, K. Joshi, G. Singh. . Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. *Cytopathology* , 23(): 181-6. . PMID 21375607
117. A. H. Lee, Z. Hodi, I. O. Ellis. . False-negative assessment of oestrogen receptor on needle core biopsy of invasive carcinoma of the breast. *J Clin Pathol* , 61(): 239-40. . PMID 18223101
118. Q. Li, A. C. Eklund, N. Juul, B. Haibe-Kains, C. T. Workman, A. L. Richardson, Z. Szallasi, C. Swanton. . Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. *PLoS One* , 5(): e15031. . PMID 21152022
119. Y. Lin, J. Hatem, J. Wang, A. Quinn, D. Hicks, P. Tang. . Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast. *Biotech Histochem* , 86(): 345-50. . PMID 20701550
120. K. P. Madeira, R. D. Daltoe, G. M. Sirtoli, L. C. Rezende, A. A. Carvalho, S. Guimaraes Idos, I. V. Silva, L. B. Rangel. . Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer. *Pathol Res Pract* , 208(): 657-61. . PMID 23017667
121. Z. P. Marinsek, N. Nolde, I. Kardum-Skelin, R. Nizzoli, B. Onal, T. Rezanko, E. Tani, K. T. Ostovic, P. Vielh, F. Schmitt, G. Kocjan. . Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates. *Cytopathology* , 24(): 7-20. . PMID 23082931
122. A. Nassar, C. Cohen, S. S. Agersborg, W. Zhou, K. A. Lynch, E. A. Barker, B. L. Vanderbilt, J. Thompson, E. R. Heyman, A. Olson, H. Lange, M. T. Siddiqui. . A multisite performance study comparing the reading of immunohistochemical slides on a computer monitor with conventional manual microscopy for estrogen and progesterone receptor analysis. *Am J Clin Pathol* , 135(): 461-7. . PMID 21350103
123. A. Nassar, C. M. Norton, D. Lawson, C. Cohen. . Image cytometric validation of breast carcinoma markers (ER, HER2 and MIB-1) using tissue microarrays: rabbit monoclonal vs. FDA-approved antibodies. *Anal Quant Cytol Histol* , 32(): 192-200. . PMID 21434519
124. A. Nassar, A. Radhakrishnan, I. A. Cabrero, G. A. Cotsonis, C. Cohen. . Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. *Appl Immunohistochem Mol Morphol* , 18(): 433-41. . PMID 20485156
125. J. P. Pachnicki, N. G. Czezko, F. Tuon, T. S. Cavalcanti, A. B. Malafaia, A. M. Tuleski. . Immunohistochemical evaluation of estrogen and progesterone receptors of pre and post-neoadjuvant chemotherapy for breast cancer. *Rev Col Bras Cir* , 39(): 86-92. . PMID 22664513
126. S. Paik. . Is gene array testing to be considered routine now?. *Breast* , 20 Suppl 3(): S87-91. . PMID 22015300
127. S. Y. Park, K. S. Kim, T. G. Lee, S. S. Park, S. M. Kim, W. Han, D. Y. Noh, S. W. Kim. . The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. *Am J Surg* , 197(): 266-9. . PMID 18614146

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

128. S. J. Payne, R. L. Bowen, J. L. Jones, C. A. Wells. . Predictive markers in breast cancer-
the present. *Histopathology* , 52(): 82-90. . PMID 18171419
129. L. Pusztai, G. Viale, C. M. Kelly, C. A. Hudis. . Estrogen and HER-2 receptor
discordance between primary breast cancer and metastasis. *Oncologist* , 15(): 1164-8. .
PMID 21041379
130. A. Qadir, S. Mushtaq, M. A. Sharif, N. Mamoon, M. T. Khadim. . Comparison of heat
induced antigen retrieval techniques for immune-histochemical estrogen receptor
expression in ductal carcinoma of breast in females. *J Coll Physicians Surg Pak* , 20(): 519-23.
. PMID 20688016
131. K. Radhika, A. K. Prayaga. . Estrogen and progesterone hormone receptor status in
breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. *Indian
J Cancer* , 47(): 148-50. . PMID 20448377
132. E. S. Reisenbichler, S. C. Lester, A. L. Richardson, D. A. Dillon, A. Ly, J. E. Brock. .
Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for
reporting ER in breast carcinomas: a demonstration of the difficulties of consistently
reporting low levels of ER expression by manual quantification. *Am J Clin Pathol* , 140(): 487-
94. . PMID 24045544
133. D. Sighoko, J. Liu, N. Hou, P. Gustafson, D. Huo. . Discordance in hormone receptor
status among primary, metastatic, and second primary breast cancers: biological difference
or misclassification?. *Oncologist* , 19(): 592-601. . PMID 24807915
134. J. Slodkowska, V. Filas, E. Buszkiewicz, P. Trzeciak, M. Wojciechowski, R. Koktysz, W.
Staniszewski, J. Breborowicz, M. G. Rojo. . Study on breast carcinoma Her2/neu and
hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako)
and ScanScope (Aperio). *Folia Histochem Cytobiol* , 48(): 19-25. . PMID 20529811
135. V. Sujoy, M. Nadji, A. R. Morales. . Brief formalin fixation and rapid tissue processing
do not affect the sensitivity of ER immunohistochemistry of breast core biopsies. *Am J Clin
Pathol* , 141(): 522-6. . PMID 24619753
136. K. Tamaki, H. Sasano, T. Ishida, M. Miyashita, M. Takeda, M. Amari, N. Tamaki, N.
Ohuchi. . Comparison of core needle biopsy (CNB) and surgical specimens for accurate
preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. *Cancer Sci* ,
101(): 2074-9. . PMID 20557310
137. V. J. Tuominen, S. Ruotoistenmaki, A. Viitanen, M. Jumppanen, J. Isola. .
ImmunoRatio: a publicly available web application for quantitative image analysis of
estrogen receptor (ER), progesterone receptor (PR), and Ki-67. *Breast Cancer Res* , 12(): R56.
. PMID 20663194
138. D. A. Turbin, S. Leung, M. C. Cheang, H. A. Kennecke, K. D. Montgomery, S.
McKinney, D. O. Treaba, N. Boyd, L. C. Goldstein, S. Badve, A. M. Gown, M. van de Rijn, T. O.
Nielsen, C. B. Gilks, D. G. Huntsman. . Automated quantitative analysis of estrogen receptor
expression in breast carcinoma does not differ from expert pathologist scoring: a tissue
microarray study of 3,484 cases. *Breast Cancer Res Treat* , 110(): 417-26. . PMID 17912629
139. A. W. Welsh, M. Harigopal, H. Wimberly, M. Prasad, D. L. Rimm. . Quantitative
analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5.
Appl Immunohistochem Mol Morphol , 21(): 139-47. . PMID 22820659

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.

140. A. W. Welsh, D. R. Lannin, G. S. Young, M. E. Sherman, J. D. Figueroa, N. L. Henry, L. Ryden, C. Kim, R. R. Love, R. Schiff, D. L. Rimm. . Cytoplasmic estrogen receptor in breast cancer. *Clin Cancer Res* , 18(): 118-26. . PMID 21980134
141. A. W. Welsh, C. B. Moeder, S. Kumar, P. Gershkovich, E. T. Alarid, M. Harigopal, B. G. Haffty, D. L. Rimm. . Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. *J Clin Oncol* , 29(): 2978-84. . PMID 21709197
142. H. Yaziji, C. R. Taylor, N. S. Goldstein, D. J. Dabbs, E. H. Hammond, B. Hewlett, A. D. Floyd, T. S. Barry, A. W. Martin, S. Badve, F. Baehner, R. W. Cartun, R. N. Eisen, P. E. Swanson, S. M. Hewitt, M. Vyberg, D. G. Hicks. . Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. *Appl Immunohistochem Mol Morphol* , 16(): 513-20. . PMID 18931614

Disclaimer

The information, data, and draft recommendations provided by the ASCO-CAP are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed public domain on April 29, 2019. These draft materials should not be stored, adapted, cited, or redistributed in any manner.